Pancreatic Cancer Research

ResearcherChinese PLA General HospitalNo recent work listed

Nan Jiang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-8460-3949; OpenAlex author ID A5009577668. Sources: OpenAlex.

Their work

Papers
3
Trials
0
Grants
0
Labs led
0
Collaborators
9
Papers, trials and grants by year

2014: 1 paper · 2015: none · 2016: none · 2017: none · 2018: none · 2019: none · 2020: 1 paper · 2021: none · 2022: 1 paper

Papers 3

  1. Nab-paclitaxel plus S-1 with or without PD-1 inhibitor in pancreatic ductal adenocarcinoma with only hepatic metastases: a retrospective cohort study. Co-author DOI 10.1007/s00423-021-02321-7↗
  2. Adjuvant nab-paclitaxel plus gemcitabine vs gemcitabine alone for resected pancreatic ductal adenocarcinoma: A single center experience in China. Co-author DOI 10.12998/wjcc.v8.i13.2778↗
  3. Decreased RGS6 expression is associated with poor prognosis in pancreatic cancer patients. Co-author PMID 25120791↗

Closest collaborators

The 9 strongest of 9 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Rong Liu · 3 shared papers, 2014–2022 · strength 0.31
  2. Zhiming Zhao · 2 shared papers, 2020–2022 · strength 0.25
  3. Shuai Xu · 1 shared paper, 2022 · strength 0.15
  4. Xiuping Zhang · 1 shared paper, 2022 · strength 0.15
  5. Qu Liu · 1 shared paper, 2022 · strength 0.15
  6. Wan Yee Lau · 1 shared paper, 2022 · strength 0.15
  7. Guanghai Dai · 1 shared paper, 2022 · strength 0.15
  8. Zhuzeng Yin · 1 shared paper, 2020 · strength 0.11
  9. Chenggang Li · 1 shared paper, 2020 · strength 0.11

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.